Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in adults: Final report of the graall-2014/b-QUEST study.

View Full Paper
Ask AI
Bookmark
Share

Authors

YHYosr HicheriInstitut Paoli-CalmettesATAnne ThiebautCentre Hospitalier Universitaire de GrenobleFOFlorence Van ObberghCliniques Universitaires Saint-Luc

Discussion

Loading...

Member takes

Implication

Phase 2 trial shows improved disease-free survival in high-risk B-cell acute lymphoblastic leukemia patients after blinatumomab consolidation, indicating better transplant outcomes.

Key Points

  • Evaluate the effectiveness of blinatumomab consolidation in high-risk Philadelphia chromosome-negative B-ALL patients.
  • Phase 2 GRAALL-2014/B-QUEST study with 94 evaluable high-risk patients.
  • Patients received blinatumomab as bridge to transplant or during consolidation and maintenance.
  • Primary endpoint assessed was 3-year disease-free survival (DFS).
  • Blinatumomab-treated patients showed 70% 3-year DFS compared to 48% in control cohort.
  • Significant improvement in complete MRD response (72% vs 55%).
  • Transplant rates post-blinatumomab increased to 88% compared to 65% in controls.

Cite This Study

Hicheri et al. (2025) studied this question.

synapsesocial.com/papers/69362f3a4fa91c937236d44ahttps://doi.org/10.1182/blood-2025-643
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab consolidation for high-risk Ph− B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study2026 · 7 citations
  2. 2Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  3. 3Blinatumomab mitigates the impact of traditional adverse prognosticators among children with standard risk b-acute lymphoblastic leukemia: Updated results of the Children's oncology group (COG) Trial AALL17312025
  4. 4Front-line treatment of Philadelphia negative B-cell acute lymphoblastic leukemia with hypercvad with blinatumomab2025 · 1 citations
  5. 5FDA Approval Summary: Blinatumomab for the Treatment of B-Cell Precursor Acute Lymphoblastic Leukemia in the Consolidation Phase of Multiphase Chemotherapy2025 · 8 citations